SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Biotechnology

Healthcare
$29.68 +2.49%

+$0.45 today

Market cap
$993.14M
Beta
-0.34
P/E (TTM)
-14.1
EPS (TTM)
-$1.32
52W Low $17.06High $32.44

Volume 0.10M

Average 0.09M

SGP Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

SpyGlass Pharma, Inc. Common StockNASDAQ: SGP

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents of $238.9M in Q1 FY2026

Q1 FY2026 cash & equivalents was $238.9M.

Context

  • Cash & equivalents amounted to 92.5% of total assets at the end of Q1 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$238.9M+147.9% QoQ
Last fiscal yearDec 2025
$96.36M— YoY
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
96.36M USD
Year-over-year change
—

Cash & Equivalents vs competitors

How SGP compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Cash & equivalents amounts to 92.5% of total assets for SGP, versus a peer median of 26.5%.
SGP Competitors
Cash & Equivalents for SGP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALCAlcon Inc.Sep 2026$1.71B USD+13.9%+15.9%5.4%
OCULOcular Therapeutix, Inc.Mar 2026$666.7M USD+90.7%+93.1%91.0%
BLCOBausch + Lomb CorporationJun 2026$367M USD+34.9%+0.3%2.6%
SGPSpyGlass Pharma, Inc. Common StockMar 2026$238.9M USD——92.5%
STAASTAAR Surgical CompanyApr 2026$131.86M USD-23.8%+21.0%29.2%
GKOSGlaukos CorporationJun 2026$114.49M USD+13.6%-8.8%12.4%
SGHTSight Sciences, Inc.Mar 2026$84.96M USD-21.9%-20.8%77.4%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$77.71M USD-8.7%+2.1%27.0%
OCSOculis Holding AGMar 2026CHF 64.37M CHF+7.5%+60.2%26.5%
RXSTRxSight, Inc.Mar 2026$17.57M USD-37.2%+19.0%5.8%
Peer median (excluding SGP) —+7.5%+15.9%26.5%

Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.